Un tratamiento de Gilead mejora la supervivencia de pacientes con linfoma B difuso de células grandes

The ZUMA-7 study demonstrates that treatment with Yescarta transforms the prognosis of aggressive lymphoma, offering significantly superior survival compared to the historical standard of chemotherapy and transplant. This advance represents a paradigm shift in oncology, positioning cellular immunotherapy as a more effective and accessible curative option than traditional protocols, which often failed in a large proportion of cases due to their complexity and toxicity. Long-term data confirm that this single-administration treatment drastically improves overall survival and progression-free survival, even in high-risk patients. By overcoming the limitations of previous treatments, where less than half of patients completed the therapeutic cycle, Yescarta offers a much higher success rate, establishing itself as the new standard of care for those who experience relapse or do not respond to first-line treatment. This evidence is crucial for the open data movement, as its simultaneous publication in *The New England Journal of Medicine* ensures that clinical results are accessible and transparent. The public availability of these rigorous findings enables the scientific community and patients to critically evaluate new therapies, fostering transparency in medical research and facilitating evidence-based decision-making—a fundamental pillar of scientific openness.

Source: que.es
Published on 2023-06-07

Un Mapa 3D de ciudades con edificios y monumentos de todo el mundo sobre los datos abiertos de OpenStreetMap »

Open Data

Related news